Antón Mónica, Cabañes Nieves, Fernández-Meléndez Salvador, Fernández-Nieto Mar, Jiménez-Ferrera Gloria, Letrán Antonio, Méndez-Brea Paula, Montoro Javier, Moreno Francisco, Mur-Gimeno Pilar, Rodríguez-Vázquez Virginia, Rosado Ana, Sánchez-Guerrero Inmaculada, Vega-Chicote Jose Mª, Vidal Carmen
Allergy Department, Hospital Universitario San Juan de Alicante, Alicante, Spain.
Allergy Department, Hospital Universitario de Toledo, Toledo, Spain.
Patient Prefer Adherence. 2023 Jul 24;17:1771-1782. doi: 10.2147/PPA.S409466. eCollection 2023.
The objective of this study was to develop and validate a questionnaire, through a Delphi consensus, to be used by allergists in their routine clinical practice to assess the preferences of patients starting allergen immunotherapy (AIT) treatment using an objective approach.
A Delphi consensus-driven process was used. The scientific committee, composed of 15 allergists, led the study and participated in the preparation of the questionnaire. Two-hundred panelists from different Spanish regions were invited to complete a 16-item questionnaire on a nine-point Likert scale covering six topic blocks. Consensus was achieved if ≥66.6% of panelists reached agreement or disagreement.
Of the 200 experts invited to participate in the Delphi process, a total of 195 (97.5%) answered the questionnaire. The panel experts reached a consensus on "agreement" on a total of 12 of the 16 (75.0%) items, covering a total of six categories: (a) patient knowledge (2 questions), (b) barriers to patient adherence (3 questions), (c) patient behavior (4 questions), (d) future actions (3 questions), (e) treatment costs (2 questions), and (f) final patient preferences (2 questions).
This Delphi consensus study validated a set of twelve recommended questions for patients objectively assessing their preferences and suitability for the most common AIT options available. The questionnaire intends to assist allergists in making an objective, unconditioned decision regarding the best AIT option for each patient, after informing them about the different routes.
本研究的目的是通过德尔菲共识法开发并验证一份问卷，供过敏症专科医生在日常临床实践中使用，以客观的方法评估开始进行变应原免疫治疗（AIT）的患者的偏好。
采用德尔菲共识驱动流程。由15名过敏症专科医生组成的科学委员会领导该研究并参与问卷编制。邀请了来自西班牙不同地区的200名专家组成专家小组，以九点李克特量表形式完成一份包含16个条目的问卷，该问卷涵盖六个主题板块。如果≥66.6%的专家小组达成一致同意或不同意意见，则达成共识。
在受邀参与德尔菲流程的200名专家中，共有195名（97.5%）回答了问卷。专家小组就16个条目中的12个（75.0%）达成了“同意”共识，共涵盖六个类别：（a）患者知识（2个问题），（b）患者依从性障碍（3个问题），（c）患者行为（4个问题），（d）未来行动（3个问题），（e）治疗费用（2个问题），以及（f）患者最终偏好（2个问题）。
这项德尔菲共识研究验证了一组十二个推荐问题，用于客观评估患者对最常见的可用AIT选项的偏好和适用性。该问卷旨在帮助过敏症专科医生在向患者告知不同治疗途径后，就每位患者的最佳AIT选项做出客观、无偏见的决策。
